BACKGROUND: Thrombelastography (TEG) and indicators of secondary and tertiary hemostasis might be altered in @entity235 with @entity5694 . HYPOTHESIS: Endotoxemia influences measures of coagulation in @entity235 . ANIMALS: Ten healthy cross-bred @entity235 . MATERIAL AND METHODS: Prospective laboratory study between controls (n = 5) receiving 0.9% saline IV and the study group (n = 5) treated with low-dose lipopolysaccharide (0.02 mg/kg IV). Physical examination and sampling for measurement of leukocytes, platelets, and coagulation variables were performed at time points 0, 1, 4, and 24 hours. Coagulation variables included @entity4563 -activated TEG, 1-stage prothrombin time (OSPT), activated partial thromboplastin time (aPTT), fibrinogen, @entity11691 , antithrombin, protein C, protein S, @entity10855 ( @entity10855 )-ratio calculated from aPTT with and without presence of @entity10855 ), and D-Dimers. RESULTS: Endotoxemia-induced clinical signs included lethargy (n = 5/5), @entity294 (n = 4/5), @entity391 (n = 4/5), and @entity490 (2/5). After 1 hour there was severe @entity1431 (2.5    0.7   10(9)/L; mean    SD, P < .0001) and a 2.2-fold increase in D-Dimers (0.81    0.64 mg/L, P < .0001). After 4 hours there was @entity221 (40.3    0.4  C, P < .0001) and increases in OSPT (10.5    2.7 seconds, P < .0001), aPTT (16.7    5.2 seconds, P = 0.002). A significant decrease in fibrinogen (1.5    1.0 g/L, P = 0.001), protein C (31    33%, P < .0001), protein S (63    47%, P < .0001), TEG a (58    19, P = .007), and TEG maximal amplitude (50    19 mm, P = .003) was seen compared with the controls. @entity10855 -ratio rose significantly (2.5    0.2, P < .0001) without exceeding the reference interval (n = 4/5). CONCLUSION AND CLINICAL IMPORTANCE: D-Dimers are the earliest indicator for @entity5694 -associated @entity854 followed by decreased protein C concentration. @entity10855 -ratio and @entity17792 were not good screening variables.

Effect of experimental @entity5694 on thrombelastography parameters, secondary and tertiary hemostasis in XXXX .

@entity5694 :: ('MESH:D019446', 'Disease') :: ['endotoxemia'] @entity11691 :: ('403875(Tax:9615)', 'Gene') :: ['factor VIII'] @entity235 :: ('9615', 'Species') :: ['dogs'] @entity4563 :: ('MESH:D007616', 'Chemical') :: ['kaolin'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity391 :: ('MESH:D014839', 'Disease') :: ['emesis'] @entity10855 :: ('MESH:D020016', 'Disease') :: ['activated protein C', 'APC'] @entity854 :: ('MESH:D018376', 'Disease') :: ['coagulation abnormalities'] @entity17792 :: ('CHEBI:44926', 'Chemical') :: ['TEG'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain'] @entity221 :: ('MESH:D005334', 'Disease') :: ['hyperthermia']
@entity235 :: (9615,Species) :: ['dogs']
